Sue-Jean Lin insider trades: Arcutis Biotherapeutics (ARQT) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Sue-Jean reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | ARQT | ↓ Sell | 4,946 | $24.38 | $121K | Direct | Jun 17, 2026 (2d) |
| Nov 24, 2025 | ARQT | ↓ Sell | 25,272 | $30.78 | $778K | Direct | Nov 25, 2025 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ARQT insiders
Open-market trades in the last 12 months
About Sue-Jean Lin's insider trades
Sue-Jean Lin is a director at Arcutis Biotherapeutics (ARQT). Since Nov 24, 2025, Sue-Jean has reported no open-market purchases and 2 sales worth $899K on SEC Form 4. In the last 12 months: 2 sales ($899K).
Their filings also include grants and awards (6 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ARQT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.